Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation

被引:51
作者
Ho, Jennifer C. [1 ]
Allen, Pamela K. [1 ]
Bhosale, Priya R. [2 ]
Rauch, Gaiane M. [2 ]
Fuller, Clifton D. [1 ]
Mohamed, Abdallah S. R. [1 ,4 ]
Frumovitz, Michael [3 ]
Jhingran, Anuja [1 ]
Klopp, Ann H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Unit 1202,1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Unit 1202,1515 Holcombe Blvd, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Unit 1202,1515 Holcombe Blvd, Houston, TX 77030 USA
[4] Univ Alexandria, Dept Clin Oncol & Nucl Med, Alexandria, Egypt
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2017年 / 97卷 / 03期
关键词
RADIATION-THERAPY; ONCOLOGY-GROUP; CONCURRENT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; 18F-FDG PET/CT; FREE SURVIVAL; STAGE IB; COEFFICIENT; PRETREATMENT; RECURRENCE;
D O I
10.1016/j.ijrobp.2016.11.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine whether apparent diffusion coefficient (ADC) value is predictive of survival after definitive chemoradiation for cervical cancer independent of established imaging and clinical prognostic factors. Methods and Materials: Between 2011 and 2013, the pretreatment MRI scans for 69 patients treated with definitive chemoradiation for newly diagnosed cervical cancer were retrieved. Scans were acquired with a 1.5-T magnetic resonance scanner, including diffusion-weighted imaging sequences. Mean ADC value was measured within a region of interest in the primary cervical cancer on the baseline MRI scan. Baseline tumor maximum standardized uptake value on positron emission tomography/computed tomography was determined by the reading radiologist. Treatment included external beam radiation therapy to the pelvis followed by brachytherapy in 97%, and with concurrent weekly cisplatin in 99% of patients. Univariate and multivariate analyses were done to investigate the association of clinical and imaging variables with disease control and survival endpoints using a Cox proportional hazard test. Results: Median follow-up was 16.7 months (range, 3.1-44.2 months). The 1-year overall survival, locoregional recurrence-free survival, and disease-free survival rates were 91%, 86%, and 74%, respectively. The median ADC value was 0.941 x 10(-3) mm(2)/s (range, 0.256-1.508 x 10(-3) mm(2)/s). The median standardized uptake value in the primary tumor was 15 (range, 6.2-43.4). In multivariate analysis, higher ADC value (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.15-0.85, P = .02), higher stage (HR 2.4, 95% CI 1.1-5.5, P = .033), and nonsquamous histology (HR 0.23, 95% CI 0.07-0.82, P = .024) were independent predictors of disease-free survival. Conclusions: The mean ADC value of the primary tumor on pretreatment MRI was the only imaging feature that was an independent predictor of disease-free survival in cervical cancer patients treated with chemoradiation. Further validation will be needed to determine whether ADC values may prove useful in identifying cervical patients at high risk of recurrence. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:546 / 553
页数:8
相关论文
共 41 条
  • [1] Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer?
    Akkas, Burcu Esen
    Demirel, Busra Bedriye
    Dizman, Aysen
    Vural, Gulin Ucmak
    [J]. ANNALS OF NUCLEAR MEDICINE, 2013, 27 (08) : 756 - 763
  • [2] Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
    不详
    [J]. NEOPLASIA, 2009, 11 (02): : 102 - 125
  • [3] Staging of uterine cervical carcinoma: whole-body diffusion-weighted magnetic resonance imaging
    Chen, Yun B.
    Hu, Chun M.
    Chen, Gui L.
    Hu, Dan
    Liao, Jiang
    [J]. ABDOMINAL IMAGING, 2011, 36 (05): : 619 - 626
  • [4] Cho SH, 2015, EUR J GYNAECOL ONCOL, V36, P30
  • [5] Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer
    Chung, Hyun Hoon
    Kim, Jae Weon
    Han, Kyung Hee
    Eo, Jae Seon
    Kang, Keon Wook
    Park, Noh-Hyun
    Song, Yong-Sang
    Chung, June-Key
    Kang, Soon-Beom
    [J]. GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 270 - 274
  • [6] Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer
    Chung, Hyun Hoon
    Nam, Byung-Ho
    Kim, Jae Weon
    Kang, Keon Wook
    Park, Noh-Hyun
    Song, Yong-Sang
    Chung, June-Key
    Kang, Soon-Beom
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (08) : 1467 - 1473
  • [7] 18F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer
    Crivellaro, Cinzia
    Signorelli, Mauro
    Guerra, Luca
    De Ponti, Elena
    Buda, Alessandro
    Dolci, Carlotta
    Pirovano, Cecilia
    Todde, Sergio
    Fruscio, Robert
    Messa, Cristina
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 131 - 135
  • [8] Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy
    Dimopoulos, Johannes C. A.
    Petrow, Peter
    Tanderup, Kari
    Petric, Primoz
    Berger, Daniel
    Kirisits, Christian
    Pedersen, Erik M.
    van Limbergen, Erik
    Haie-Meder, Christine
    Poetter, Richard
    [J]. RADIOTHERAPY AND ONCOLOGY, 2012, 103 (01) : 113 - 122
  • [9] Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix
    Eifel, PJ
    Jhingran, A
    Brown, J
    Levenback, C
    Thames, H
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (03) : 1106 - 1111
  • [10] Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01
    Eifel, PJ
    Winter, K
    Morris, M
    Levenback, C
    Grigsby, PW
    Cooper, J
    Rotman, M
    Gershenson, D
    Mutch, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 872 - 880